This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


PanOptica, Inc.

Drug Names(s): PAN90806 Ophthalmic Solution

Description: PAN-90806 is an inhibitor of VEGF, a protein that plays a critical role in angiogenesis (the formation of new blood vessels) and increased blood vessel permeability (leakage from blood vessels).

Deal Structure: OSI (Astellas) and PanOptica
In January 2010, PanOptica announced that it had licensed exclusive worldwide ophthalmic rights to PAN-90806 from OSI Pharmaceuticals, a wholly owned subsidiary of Astellas in exchange for up-front cash, equity interest in PanOptica, and potential future milestones and royalties. Financial terms of the agreement have not been disclosed.

Partners: Astellas Pharma, Inc.

PAN-90806 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug